Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer
Executive Summary
The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.
You may also be interested in...
Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.
First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
BeyondSpring’s Pivotal NSCLC Trial For Plinabulin Designed To Avoid Bavencio’s JAVELIN 200 Failure
Lessons learned about blinding and stratification from Pfizer and Merck KGaA’s earlier Phase III disappointment shaped the design of BeyondSpring's ongoing Phase III trial of plinabulin in second- and third-line non-small cell lung cancer.